Trial Information
Prospective Evaluation of Plasma EBV DNA Half-life and PET-CT Scanning as a New Tool in Assessing Early Response to Chemotherapy in Patients With Advanced Nasopharyngeal Carcinoma
Inclusion Criteria:
- undergo chemotherapy for any one of the following settings:
1. Setting 1: Neoadjuvant chemotherapy prior to cheom-RT
2. Setting 2: Palliative chemotherapy in Chemonaive patients
3. Setting 3: Palliative chemotherapy in previously treated patients (i.e. 2nd
line or 3rd line chemo)
- Age >= 18 years
- (ECOG) performance status of 0-2
- have detectable levels of pEBV DNA at baseline
- have measurable tumor sites by RECIST criteria
- have adequate bone marrow, renal and hepatic functions
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
To determine if measuring tumor metabolic response during chemotherapy can predict survival
Outcome Time Frame:
3 years
Safety Issue:
No
Principal Investigator
Brigette Ma, MD, FRCP
Investigator Role:
Principal Investigator
Investigator Affiliation:
Chinese University of Hong Kong
Authority:
Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee
Study ID:
NPC023
NCT ID:
NCT01365208
Start Date:
July 2011
Completion Date:
May 2014
Related Keywords:
- Advanced Nasopharyngeal Carcinoma
- Carcinoma
- Nasopharyngeal Neoplasms